Sanofi's Trading Volume Surges 64% to 406th Position Amidst Phase 3 Trial Controversy

On June 20, 2025, Sanofi's trading volume reached 2.18 billion, marking a 64.06% increase from the previous day. This surge placed Sanofi at the 406th position in the day's trading volume rankings. Sanofi's stock price rose by 0.48%.

Bronstein, Gewirtz & Grossman, LLC is conducting an investigation into potential claims on behalf of Sanofi shareholders. The investigation follows Sanofi's announcement on May 30, 2025, regarding its Phase 3 program for itepekimab, an antibody treatment for chronic obstructive pulmonary disease (COPD). While the primary endpoint was met in one late-stage trial, a second trial failed to achieve the same result. This mixed outcome led to a significant drop in Sanofi's American Depositary Receipts (ADRs) on the same day.

Investors who have purchased Sanofi securities are encouraged to visit the firm's website for more information and to assist in the investigation. The firm represents investors in securities fraud class actions and shareholder derivative suits, having recovered hundreds of millions of dollars for investors nationwide. The firm operates on a contingency fee basis, meaning they will only seek reimbursement for out-of-pocket expenses and attorneys' fees if the case is successful.